drugset / Trial / NCT03002038

Comparison of Clinical Effects of Azathioprine and Rituximab NMO-SD Patients

NCT03002038 ↗

Phase 2/3 Completed 86 enrolled Isfahan University of Medical Sciences
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to compare annual relapse rate, expanded disability status scale, and side effects of azathioprine and rituximab in patients with neuromyelitis optica spectrum disorder during a one year follow up through a randomized clinical trial.

Timeline

Start
2015-09
Primary completion
2016-11
Completion
2016-12

Outcome

Met primary endpoint

paper ARR after intervention minus ARR before intervention [mean (SD)] was 1.09 (0.72) in RIT group and 0.49 (0.59) in AZA group (P value <0.001). PMID 28831548 ↗

paper RIT was significantly more effective than AZA treatment. PMID 28831548 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Azathioprine Small molecule 3 g Oral
Subject Rituximab Monoclonal antibody 1 g Intravenous

Indications